Three new US Patents for the Australian Life Science sector

280 Life Science patents (classification A61K) were issued by the US Patent and Trademark Office on Tuesday 4 October 2016 (click here). Three went to Australian assignees.

US Patent 9,458,093 went to Vectus Biosystems (ASX: VBS) for ​Compositions for the treatment of hypertension and/or fibrosis​​. This patent covers the use of vasoactive intestinal peptide (VIP) fragment in these two conditions.   

US Patent 9,457,107 went to the  ​University of Melbourne for Cage amine ligands for metallo-radiopharmaceuticals. This patent covers metal-binding organic compounds that could be useful in radiotherapy.

US Patent 9,457,062 went to Invion (ASX: IVX) for Chaperonin 10-induced immunomodulation. This patent covers chaperonin 10 polypeptides, useful for activating Toll-Like Receptors.

​Over the last twelve months the Australian Life Science sector has been granted 123 US patents, versus 129 in the previous corresponding period. ​

To look at US Life Science patent issuance since the beginning of 2014 to Australian assignees, click here. For  US Life Science patent issuance to New Zealand assignees click here.